SCHEMBL5838259

SCHEMBL5838259

CCCCCCC1(C(=O)NCCN(CC)CC)CCc2c(C)c(O)c(C)c(C)c2O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
CYP4F2 P78329 1/20 0.39
PSEN1 P49768 3/20 0.38
NR1I2 O75469 2/20 0.38
ALOX5 P09917 1/20 0.38
BCHE P06276 8/20 0.38
ACHE P22303 8/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.37
GSTP1 P09211 1/20 0.37
TTPA P49638 1/20 0.37
KMT2A Q03164 1/20 0.37
USP2 O75604 1/20 0.37
THRB P10828 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5838132 1.00 PTGS1 (0.41) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL5838428 0.81 PTGS1 (0.60) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL5839232 0.81 PTGS1 (0.55) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL5839783 0.81 PTGS1 (0.55) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL5839664 0.79 CYP4F2 (0.44) CYP4F2PSEN1NR1I2ALOX5MAPT
SCHEMBL5837974 0.79 CYP4F2 (0.44) CYP4F2PSEN1NR1I2ALOX5MAPT
SCHEMBL2059199 0.76 PTGS1 (0.61) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL9314334 0.76 PTGS1 (0.61) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL16247653 0.76 PTGS1 (0.61) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL5838134 0.74 ALDH1A1 (0.33) TSHRALOX5ACHELMNACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115657-B2 Bifunctional agents possessing antioxidant and antiarrhythmic activity UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2006-10-03 US disclosed
US-20040259763-A1 Bifunctional agents possessing antioxidant and antiarrhythmic activity UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) 2004-12-23 US disclosed
EP-1301504-B1 BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) 2004-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259763-A1 Bifunctional agents possessing antioxidant and antiarrhythmic activity GPX4, GSR, GPX1 PTGS1 316/4885PTGS2 275/4885CYP1A2 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.